Research & Development

At BioGenomics, R&D efforts are primarily in recombinant DNA technologies. BioGenomics has a team of molecular biologists, microbiologists, protein chemists and fermentation technologists to develop a range of recombinant products such as therapeutic proteins and enzymes.

BioGenomics has a fully- integrated biopharmaceutical drug discovery facility and has the potential for rapidly completing the development of products, from the research stage to full- fledged commercial manufacturing.

Research in recombinant DNA based drug discovery is mainly in these principle areas:

Molecular Cloning and Expression in Prokaryotes
Molecular Cloning and Expression in Eukaryotes
Microbiology and Strain Improvement
Cell Line Development
Fermentation Technology
Protein Folding and Purification Strategies
Formulations of Biologics and Biopharmaceuticals

Pipeline

BioGenomics’ product pipeline includes therapeutic biomolecules arising via recombinant proteins derived from microbial and mammalian cell culture based fermentation technologies. Future product development is mainly in the area of hematology, oncology, orthopedics and infectious diseases.

Facility

Research Facility

To explore the scientific creativity of a scientist, a conducive environment is a primary requisite. BioGenomics has developed a state-of-art research facility equipped with the latest tools of research in modern biotechnology, providing the scientists with the necessary wherewithal to carry on their work. BioGenomics is equipped with a very modern R&D facility, suited for the development of recombinant biotechnology based drugs.

Molecular Biology
Microbial Strain Development
Mammalian Cell Culture and Strain Development
Downstream Purification
Pilot Plant for Microbial and Mammalian Platforms
Protein Characterization

Manufacturing Facility

The manufacturing facility, situated at Puducherry, has full- fledged upstream, downstream and formulation facilities required for recombinant therapeutic proteins and meets international cGMP standards and complies with environmental biosafety regulations. The facility has been built and validated by international experts in biopharmaceutical plant design and construction.

The facility has 20,000 sq. ft. of laboratory area, divided in four independent laboratories.

Instrument Facility

• Automatic computer controlled bio-reactors of various capacities from 3L to 300L for microbial and mammalian cell culture Cross-flow filtration systems of various types such as membrane, hollow fibre and

•ceramic, for handling filtration process upto a volume of 1000L.
•Continuous flow centrifuge for handling large-scale separation processes upto a volume of 500L.
•Homogenisers including a bead-mill and a high-pressure homogeniser for pilot scale cell disruption.
•Sophisticated computer controlled chromatography systems for laboratory and pilot
•scale protein purification along with axial and radial flow and expanded bed columns of various sizes.
•LC-MS/ MALDI-TOF for protein characterization
•Automated DNA Sequencer
•Pilot scale lyophilisers for aseptic freeze-drying.
•Dry heat and steam sterilising equipments.
•Other analytical instruments include Fluorescence and phase-contrast microscopes with camera and video attachments, Scanning Densitometer, Gel Documentation System, UV-VIS Spectrophotometer, Spectroflourimeter, HPCL, Thermocyclers etc.<